Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Genomic characterization of IDH-mutant astrocytoma progression to grade 4 in the treatment setting.

Acta neuropathologica communications - 6 Nov 2023

Rautajoki Kirsi J, Jaatinen Serafiina, Hartewig Anja, Tiihonen Aliisa M, Annala Matti, Salonen Iida, Valkonen Masi, Simola Vili, Vuorinen Elisa M, Kivinen Anni, Rauhala Minna J, Nurminen Riikka, Maass Kendra K, Lahtela Sirpa-Liisa, Jukkola Arja, Yli-Harja Olli, Helén Pauli, Pajtler Kristian W, Ruusuvuori Pekka, Haapasalo Joonas, Zhang Wei, Haapasalo Hannu, Nykter Matti

Abstract excerpt

As the progression of low-grade diffuse astrocytomas into grade 4 tumors significantly impacts patient prognosis, a better understanding of this process is of paramount importance for improved patient care. In this project, we analyzed matched IDH-mutant astrocytomas before and after progression to grade 4 from six patients (discovery cohort) with genome-wide sequencing, 21 additional patients with targeted...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Astrocytoma

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Brain Neoplasms

Share to Genomics

Share to Glioma

Share to Isocitrate Dehydrogenase

Share to Mutation

Share to Temozolomide

Source

Open in PubMed Open full text

Identifiers

PMID: 37932833
DOI: 10.1186/s40478-023-01669-9
PMCID: PMC10629206

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genomic characterization of IDH-mutant astrocytoma progression to grade 4 in the treatment setting.PMID 37932833Read ↗

Genetic and epigenetic instability as an underlying driver of progression and aggressive behavior in IDH-mutant astrocytoma.Semantic proximity Read ↗

Tumor-initiating genetics and therapy drive divergent molecular evolution in IDH-mutant gliomasSemantic proximity Read ↗

Clinical Implications of Aberrant Retinoblastoma Signaling in Patients With Grade 4 IDH-Mutant Astrocytoma: A Retrospective Cohort Study.Semantic proximity Read ↗

Molecular markers related to patient outcome in patients with IDH-mutant astrocytomas grade 2 to 4: A systematic review.Semantic proximity Read ↗

A multi-center, clinical analysis of IDH-mutant gliomas, WHO Grade 4: implications for prognosis and clinical trial design.Semantic proximity Read ↗

Molecular Characterization of Astrocytoma Progression Towards Secondary Glioblastomas Utilizing Patient-Matched Tumor PairsSemantic proximity Read ↗

IDH-mutant grade 4 astrocytoma: a comparison integrating the clinical, pathological, and survival features between primary and secondary patients.Semantic proximity Read ↗

Rapid progression to glioblastoma in a subset of IDH-mutated astrocytomas: a genome-wide analysis.Semantic proximity Read ↗

The genetic landscape of gliomas arising after therapeutic radiation.Semantic proximity Read ↗

Genetic alterations that deregulate RB and PDGFRA signaling pathways drive tumor progression in IDH2-mutant astrocytoma.Semantic proximity Read ↗

Integrated genomic characterization of IDH1-mutant glioma malignant progression.Semantic proximity Read ↗

Long-term outcomes in IDH-wildtype (IDH-wt) gliomas with historical WHO grade 2 and 3 histology.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.